Emerging studies suggest Retatrutide , a dual activator targeting both incretin and glucose-dependent insulinotropic polypeptide , could represent a significant advancement for obesity treatment. Preliminary patient tests have demonstrated impressive decreases in visceral fat , potentially outperforming current weight-loss therapies . Despite this,